{"id":6007,"date":"2026-06-23T22:38:40","date_gmt":"2026-06-23T22:38:40","guid":{"rendered":"https:\/\/99puritypeptides.com\/?p=6007"},"modified":"2026-06-24T01:41:08","modified_gmt":"2026-06-24T01:41:08","slug":"tesamorelin-visceral-fat-reduction-percentage","status":"publish","type":"post","link":"https:\/\/99puritypeptides.com\/es\/tesamorelin-visceral-fat-reduction-percentage\/","title":{"rendered":"Tesamorelin &amp; Visceral Fat: Phase 3 VAT Reduction Data (2026)"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/06\/visceral-adipose-tissue-around-organs.webp&#8221; parallax=&#8221;on&#8221; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; min_height=&#8221;541px&#8221; min_height_tablet=&#8221;541px&#8221; min_height_phone=&#8221;220px&#8221; min_height_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#08171a&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#7c7c7c&#8221; text_font_size=&#8221;14px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Last updated: June 24, 2026<\/p>\n<p>[\/et_pb_text][et_pb_heading title=&#8221;Tesamorelin &#038; Visceral Fat: What the Phase 3 Clinical Trials Actually Show&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;32px&#8221; width=&#8221;81%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_2_font=&#8221;|600|||||||&#8221; header_2_text_color=&#8221;#FFFFFF&#8221; header_2_font_size=&#8221;22px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|700|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Few research peptides have a clinical record as specific as tesamorelin. Across multiple Phase 3 trials, the <strong>tesamorelin visceral fat reduction percentage<\/strong> has been measured directly with CT imaging, and the results are remarkably consistent. Researchers searching for hard numbers \u2014 not vague promises \u2014 keep arriving at the same question: how much visceral adipose tissue does this growth hormone-releasing hormone analog actually reduce, and how quickly?<\/p>\n<p>This guide answers that question first, then explains the science behind it. You will find the measured VAT reduction percentage, the 26-week timeline, the mechanism of action, and how tesamorelin compares with other metabolic research peptides. Because the data comes from registrational human trials, the figures are unusually well documented. Throughout, the focus stays on research context, and every product referenced is intended strictly for laboratory study.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; background_color=&#8221;#70a6ff&#8221; custom_padding=&#8221;10px|10px|10px|10px|true|true&#8221; border_radii=&#8221;on|8px|8px|8px|8px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span style=\"color: #ffffff;\"><strong>Quick answer<\/strong><\/span><\/p>\n<p>In Phase 3 clinical trials, tesamorelin reduced visceral adipose tissue (VAT) by approximately 15\u201318% at 26 weeks, measured by CT scan at the L4\u2013L5 vertebral level. The reduction was significant compared with placebo, appeared by week 13, and largely reversed when the peptide was discontinued \u2014 indicating that continued administration was required to maintain the effect.<\/p>\n<p>[\/et_pb_text][et_pb_heading title=&#8221;What Is Tesamorelin?&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_2_font=&#8221;|600|||||||&#8221; header_2_text_color=&#8221;#FFFFFF&#8221; header_2_font_size=&#8221;22px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|700|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Tesamorelin is a synthetic <strong>growth hormone-releasing hormone (GHRH) analog<\/strong> \u2014 a stabilized 44-amino-acid peptide that signals the pituitary gland to release the body&#8217;s own growth hormone in a natural, pulsatile pattern. Unlike direct growth hormone administration, it works one step upstream, which is why it became a subject of intense clinical interest for visceral fat research.<\/p>\n<p>It was first studied for HIV-associated lipodystrophy, a condition marked by excess visceral adipose tissue. That research context is important: the Phase 3 trials were specifically designed to measure VAT change, so the <strong>tesamorelin visceral fat reduction percentage<\/strong> is one of the best-documented efficacy figures in the entire peptide literature.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/06\/labeled-molecular-diagram-of-tesamorelin.webp&#8221; parallax=&#8221;on&#8221; min_height=&#8221;300px&#8221; custom_margin=&#8221;25px||||false|false&#8221; border_radii=&#8221;on|8px|8px|8px|8px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider show_divider=&#8221;off&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; height=&#8221;501px&#8221; height_tablet=&#8221;501px&#8221; height_phone=&#8221;501px&#8221; height_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; make_equal=&#8221;on&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; parallax=&#8221;on&#8221; custom_margin=&#8221;50px||50px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_enable_image=&#8221;off&#8221; border_radii=&#8221;on|12px|12px|12px|12px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider show_divider=&#8221;off&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; height_tablet=&#8221;650px&#8221; height_phone=&#8221;420px&#8221; height_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|700|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><strong>Key facts at a glance:<\/strong><\/h3>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_2_font=&#8221;|600|||||||&#8221; header_2_text_color=&#8221;#FFFFFF&#8221; header_2_font_size=&#8221;22px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|700|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<ul>\n<li>Class: Growth hormone-releasing hormone (GHRH) analog<\/li>\n<li>Structure: Stabilized 44-amino-acid peptide chain<\/li>\n<li>Primary research endpoint: Visceral adipose tissue (VAT) reduction<\/li>\n<li>Measured effect: ~15\u201318% VAT reduction at 26 weeks in Phase 3 trials<\/li>\n<li>Mechanism: Stimulates endogenous, pulsatile growth hormone release<\/li>\n<li>Reversibility: Effect diminishes after discontinuation<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;The Tesamorelin Phase 3 Findings (Science-Backed)&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The following findings are drawn from registrational Phase 3 trials and their published analyses. Each one is framed for research interpretation.<\/p>\n<ol>\n<li><strong>Roughly 15\u201318% VAT reduction. <\/strong>The headline result: visceral adipose tissue fell by approximately 15\u201318% at 26 weeks versus a slight increase under placebo, measured by single-slice CT.<\/li>\n<li><strong>Effect appeared by week 13. <\/strong>Interim measurement showed meaningful VAT separation from placebo at the halfway point, indicating a relatively rapid onset.<\/li>\n<li><strong>Subcutaneous fat was largely spared. <\/strong>The reduction was selective for visceral fat; subcutaneous adipose tissue changed comparatively little, a key distinction in the research data.<\/li>\n<li><strong>Triglycerides improved. <\/strong>Trials reported reductions in triglycerides and improvements in several lipid parameters alongside the VAT change.<\/li>\n<li><strong>IGF-1 rose as expected. <\/strong>Because tesamorelin stimulates growth hormone release, insulin-like growth factor 1 (IGF-1) increased \u2014 a pharmacodynamic marker confirming target engagement.<\/li>\n<li><strong>The effect was reversible. <\/strong>When the peptide was withdrawn, visceral fat tended to return, showing that continued administration was needed to sustain the reduction.<\/li>\n<li><strong>Liver fat signals. <\/strong>Later research extended interest to hepatic fat, with studies examining tesamorelin&#8217;s effect on liver fat fraction in fatty-liver models.<\/li>\n<\/ol>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Why Does Tesamorelin Reduce Visceral Fat?&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The mechanism explains why the <strong>tesamorelin visceral fat reduction percentage<\/strong> is so selective. The peptide drives a chain of signaling events that preferentially mobilizes visceral fat:<\/p>\n<ul>\n<li>It binds GHRH receptors on the pituitary, prompting natural growth hormone pulses.<\/li>\n<li>Growth hormone promotes lipolysis \u2014 the breakdown of stored triglycerides.<\/li>\n<li>Visceral adipose tissue is especially sensitive to growth hormone-driven lipolysis.<\/li>\n<li>The pulsatile pattern mimics physiological release, unlike steady exogenous growth hormone.<\/li>\n<li>Elevated IGF-1 reflects downstream activity and serves as a research biomarker.<\/li>\n<\/ul>\n<p>This upstream approach is the reason tesamorelin reduces visceral fat more selectively than blunt growth hormone administration, while leaving subcutaneous stores comparatively intact.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=&#8221;on&#8221; make_equal=&#8221;on&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; parallax=&#8221;on&#8221; custom_margin=&#8221;50px||50px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_enable_image=&#8221;off&#8221; border_radii=&#8221;on|12px|12px|12px|12px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider show_divider=&#8221;off&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; height_tablet=&#8221;650px&#8221; height_phone=&#8221;420px&#8221; height_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][et_pb_heading title=&#8221;Tesamorelin vs Other Metabolic Research Peptides&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Researchers frequently compare tesamorelin with other compounds studied for fat metabolism. The table summarizes how they differ in mechanism and primary research endpoint.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<table class=\"responsive-peptide-table\">\n<thead>\n<tr>\n<th><span style=\"color: #33cccc;\">Peptide<\/span><\/th>\n<th><span style=\"color: #33cccc;\">Class \/ Mechanism<\/span><\/th>\n<th><span style=\"color: #33cccc;\">Primary Research Endpoint<\/span><\/th>\n<th><span style=\"color: #33cccc;\">Key Distinction<\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td data-label=\"Peptide\"><strong>Tesamorelin<\/strong><\/td>\n<td data-label=\"Class \/ Mechanism\">GHRH analog (stimulates GH)<\/td>\n<td data-label=\"Primary Research Endpoint\">Visceral fat (VAT) reduction<\/td>\n<td data-label=\"Key Distinction\">~15\u201318% VAT reduction at 26 weeks; selective for visceral fat<\/td>\n<\/tr>\n<tr>\n<td data-label=\"Peptide\"><strong>Retatrutide<\/strong><\/td>\n<td data-label=\"Class \/ Mechanism\">Triple GLP-1\/GIP\/glucagon agonist<\/td>\n<td data-label=\"Primary Research Endpoint\">Total body weight reduction<\/td>\n<td data-label=\"Key Distinction\">Broad weight loss effects; not VAT-selective<\/td>\n<\/tr>\n<tr>\n<td data-label=\"Peptide\"><strong>AOD-9604<\/strong><\/td>\n<td data-label=\"Class \/ Mechanism\">GH fragment (176\u2013191)<\/td>\n<td data-label=\"Primary Research Endpoint\">Lipolysis research<\/td>\n<td data-label=\"Key Distinction\">Fragment of GH; does not elevate IGF-1<\/td>\n<\/tr>\n<tr>\n<td data-label=\"Peptide\"><strong>CJC-1295<\/strong><\/td>\n<td data-label=\"Class \/ Mechanism\">GHRH analog<\/td>\n<td data-label=\"Primary Research Endpoint\">GH\/IGF-1 elevation<\/td>\n<td data-label=\"Key Distinction\">Longer half-life; broader GH-related effects<\/td>\n<\/tr>\n<tr>\n<td data-label=\"Peptide\"><strong>MOTS-c<\/strong><\/td>\n<td data-label=\"Class \/ Mechanism\">Mitochondrial-derived peptide<\/td>\n<td data-label=\"Primary Research Endpoint\">Metabolic regulation<\/td>\n<td data-label=\"Key Distinction\">Acts on metabolic signaling pathways rather than direct lipolysis<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/06\/visceral-vs-subcutaneous-fat-comparison.webp&#8221; parallax=&#8221;on&#8221; min_height=&#8221;300px&#8221; custom_margin=&#8221;25px||||false|false&#8221; border_radii=&#8221;on|8px|8px|8px|8px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider show_divider=&#8221;off&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; height=&#8221;501px&#8221; height_tablet=&#8221;501px&#8221; height_phone=&#8221;501px&#8221; height_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;2_3,1_3&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;How Well-Characterized Is Tesamorelin in Research?&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Because tesamorelin progressed through registrational trials, its research profile is unusually well documented. Trial data captured pharmacodynamic markers such as IGF-1, glucose parameters, and lipid panels across hundreds of subjects, giving researchers a detailed reference set. In laboratory settings, the compound&#8217;s stability, reconstitution behavior, and storage requirements are equally important variables to control.<\/p>\n<p><strong>Research handling considerations:<\/strong><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li>Lyophilized peptide should be stored cold and protected from light until reconstitution.<\/li>\n<li>Reconstitution typically uses bacteriostatic water; concentration math can be confirmed with the <a href=\"https:\/\/99puritypeptides.com\/peptide-reconstitution-calculator\/\">peptide reconstitution calculator<\/a>.<\/li>\n<li>Once reconstituted, the solution is generally refrigerated and used within a defined window.<\/li>\n<li>Purity verification via a <a href=\"\/certificates\">certificate of analysis<\/a> (COA) is essential for reproducible results.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/06\/visceral-adipose-tissue-around-organs-1-1.webp&#8221; alt=&#8221;visceral adipose tissue around organs&#8221; title_text=&#8221;visceral-adipose-tissue-around-organs-1-1&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Tesamorelin in Visceral Fat &#038; Metabolic Research&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The original research population \u2014 subjects with excess visceral adipose tissue \u2014 made tesamorelin a natural model compound for studying central adiposity. Visceral fat is metabolically active and associated with lipid and glucose dysregulation, so a compound that selectively reduces it offers a clean research model. This is why the <strong>tesamorelin visceral fat reduction percentage<\/strong> remains a reference figure in metabolic peptide studies.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/06\/reconsitituition-vial-and-bacteristatic-water.webp&#8221; parallax=&#8221;on&#8221; min_height=&#8221;300px&#8221; custom_margin=&#8221;25px||||false|false&#8221; border_radii=&#8221;on|8px|8px|8px|8px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider show_divider=&#8221;off&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; height=&#8221;501px&#8221; height_tablet=&#8221;501px&#8221; height_phone=&#8221;501px&#8221; height_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;The GHRH Analog Advantage: Why the Mechanism Matters&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Tesamorelin&#8217;s status as a GHRH analog \u2014 rather than direct growth hormone \u2014 is central to interpreting its data. By prompting the pituitary to release the body&#8217;s own growth hormone in pulses, it preserves physiological feedback loops. The hypothalamic-pituitary axis can still modulate output, which differentiates the research profile from steady exogenous growth hormone.<\/p>\n<p>For researchers, this means IGF-1 elevation serves as a built-in pharmacodynamic readout, and the visceral-fat selectivity becomes easier to explain mechanistically. The peptide&#8217;s stabilized structure also extends its functional half-life compared with native GHRH, which degrades rapidly.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Tesamorelin in Emerging Research (2025\u20132026)&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Interest has expanded well beyond the original visceral-fat endpoint. Recent investigative directions include:<\/p>\n<ul>\n<li>Hepatic fat: studies examining liver fat fraction and fatty-liver research models.<\/li>\n<li>Cognitive research: exploratory work on growth hormone axis signaling and brain aging.<\/li>\n<li>Cardiometabolic markers: continued analysis of lipid and inflammatory parameters.<\/li>\n<li>Combination protocols: comparative research alongside other metabolic peptides.<\/li>\n<\/ul>\n<p>These directions keep tesamorelin relevant in the latest research conversations and reinforce its position as a well-characterized reference compound.<\/p>\n<h3><strong><span style=\"color: #33cccc;\"><br \/>Reconstitution &amp; Concentration in Tesamorelin Research<\/p>\n<p><\/span><\/strong><\/h3>\n<p>Accurate concentration is critical when interpreting any VAT research figure. Inconsistent reconstitution introduces variability that can obscure results. Researchers typically:<\/p>\n<ul>\n<li>Calculate target concentration before adding bacteriostatic water.<\/li>\n<li>Add diluent slowly down the vial wall to protect the peptide.<\/li>\n<li>Swirl rather than shake to avoid mechanical degradation.<\/li>\n<li>Confirm unit math using the <a href=\"https:\/\/99puritypeptides.com\/peptide-calculator\/\">peptide calculator<\/a>.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;How to Reference Tesamorelin in Research Protocols&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>In documented protocols, tesamorelin is handled as a lyophilized research peptide: reconstituted with bacteriostatic water, stored cold, and logged against a certificate of analysis. Consistent handling is what makes the visceral fat reduction data reproducible across studies. Researchers sourcing reference material should prioritize verified purity and documented COAs over price alone.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/99puritypeptides.com\/product\/tesamorelin\/&#8221; button_text=&#8221;View Tesamorelin Research Specifications&#8221; button_alignment=&#8221;center&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; button_text_size=&#8221;16px&#8221; button_border_radius=&#8221;8px&#8221; button_font=&#8221;|600||on|||||&#8221; custom_margin=&#8221;30px||||false|false&#8221; custom_padding=&#8221;15px|20px|15px|20px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;What Makes 99 Purity Peptides Different?&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Reproducible research depends on reproducible inputs. 99 Purity Peptides supplies reference-grade research compounds with documentation built for laboratory standards:<\/p>\n<ul>\n<li>Third-party tested purity with published certificates of analysis (COA).<\/li>\n<li>Lyophilized peptides handled and shipped to preserve stability.<\/li>\n<li>Exact-milligram labeling for precise concentration math.<\/li>\n<li>Research-use-only framing with transparent specifications.<\/li>\n<li>Free dosing and concentration tools, including the <a href=\"https:\/\/99puritypeptides.com\/peptide-reconstitution-calculator\/\">reconstitution calculator<\/a>.<\/li>\n<\/ul>\n<h3><span style=\"color: #33cccc;\"><strong>Lyophilized vs Reconstituted Tesamorelin: What the Research Shows<\/strong><\/span><\/h3>\n<p>Tesamorelin is supplied lyophilized (freeze-dried) because the peptide is more stable in dry form. Reconstituted solution has a shorter usable window and must be refrigerated. For research storage, the lyophilized form is preferred for long-term reference material, while reconstituted solution is prepared close to the time of use.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;\/shop&#8221; button_text=&#8221;Explore Research Peptides&#8221; button_alignment=&#8221;center&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; button_text_size=&#8221;16px&#8221; button_border_radius=&#8221;8px&#8221; button_font=&#8221;|600||on|||||&#8221; custom_margin=&#8221;30px||||false|false&#8221; custom_padding=&#8221;15px|20px|15px|20px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3><span style=\"color: #33cccc;\"><strong><\/strong><\/span><\/h3>\n<h3><span style=\"color: #33cccc;\"><strong>Tesamorelin vs Retatrutide: Understanding the Difference<\/strong><\/span><\/h3>\n<p>These two compounds are often searched together, but they model different things. Tesamorelin is a GHRH analog studied specifically for <strong>visceral<\/strong> fat reduction, with a measured VAT percentage. Retatrutide is a triple-agonist studied for broad body-weight change. A researcher modeling central adiposity selectively would reference tesamorelin; one modeling global weight change would reference retatrutide. They are complementary reference points, not substitutes.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;The Future of Tesamorelin Research&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Tesamorelin&#8217;s well-documented Phase 3 record makes it a durable reference compound. As research extends into hepatic fat, cardiometabolic markers, and combination protocols, the original visceral fat reduction data remains the anchor figure. Its mechanism \u2014 pulsatile, upstream, and selective \u2014 continues to make it a model peptide for metabolic study, and the latest 2025\u20132026 research keeps building on that foundation.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Conclusion: What the Tesamorelin Visceral Fat Data Tells Researchers&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|-390px||||&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; header_3_font=&#8221;&#8211;et_global_heading_font|500|||||||&#8221; header_3_text_color=&#8221;#FFFFFF&#8221; header_3_font_size=&#8221;20px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Across Phase 3 trials, the <strong>tesamorelin visceral fat reduction percentage<\/strong> lands consistently near 15\u201318% at 26 weeks, with effects appearing by week 13, selectivity for visceral over subcutaneous fat, and reversibility on discontinuation. Few research peptides offer this level of documented, CT-measured specificity. For laboratories seeking a well-characterized metabolic reference compound, tesamorelin remains one of the most rigorously studied options available \u2014 and reproducible results start with verified, reference-grade material.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#000000&#8243; custom_margin=&#8221;60px||||false|false&#8221; custom_padding=&#8221;60px|40px|60px|40px|true|true&#8221; custom_padding_tablet=&#8221;||80px||false|false&#8221; custom_padding_phone=&#8221;||80px||false|false&#8221; border_radii=&#8221;on|20px|20px|20px|20px&#8221; border_width_all=&#8221;1px&#8221; border_color_all=&#8221;#1E5D68&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Start Your Research Today&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_align=&#8221;center&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; title_line_height=&#8221;1.2em&#8221; width=&#8221;100%&#8221; custom_margin_tablet=&#8221;15px||||false|false&#8221; custom_margin_phone=&#8221;30px||||false|false&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; text_orientation=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div>\n<div>Every Tesamorelin vial we supply ships with full third-party Certificate of Analysis documentation \u2014 so your research begins with verified purity, not assumptions.<\/div>\n<\/div>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/99puritypeptides.com\/product\/tesamorelin\/&#8221; button_text=&#8221;Start Your Research Today&#8221; button_alignment=&#8221;center&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; button_text_size=&#8221;16px&#8221; button_border_radius=&#8221;8px&#8221; button_font=&#8221;|600||on|||||&#8221; custom_margin=&#8221;30px||||false|false&#8221; custom_padding=&#8221;15px|20px|15px|20px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; custom_padding_last_edited=&#8221;on|tablet&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#0a0202&#8243; background_enable_image=&#8221;off&#8221; background_position=&#8221;center_right&#8221; custom_padding=&#8221;||||true|false&#8221; custom_padding_tablet=&#8221;||||false|false&#8221; custom_padding_phone=&#8221;||||true|false&#8221; custom_css_free_form=&#8221;@media (max-width: 1024px) and (min-width: 981px){|| selector {|| padding: 60px 0px 70px !important; ||}||}&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Questions&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Montserrat|700|||||||&#8221; title_text_align=&#8221;center&#8221; title_text_color=&#8221;#ffffff&#8221; title_font_size=&#8221;32px&#8221; title_line_height=&#8221;42px&#8221; custom_margin=&#8221;0px||0px||true|false&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#fafafa&#8221; text_line_height=&#8221;26px&#8221; text_orientation=&#8221;center&#8221; custom_margin=&#8221;0px||0px||true|false&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Frequently Asked Questions About GHK-Cu<\/strong><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=&#8221;on|tablet&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; width=&#8221;60%&#8221; width_tablet=&#8221;90%&#8221; width_phone=&#8221;90%&#8221; width_last_edited=&#8221;on|tablet&#8221; custom_margin=&#8221;30px||||false|false&#8221; custom_margin_tablet=&#8221;20px||||false|false&#8221; custom_margin_phone=&#8221;20px||||false|false&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; custom_padding_tablet=&#8221;0px||||false|false&#8221; custom_padding_phone=&#8221;0px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_code _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<style><!-- [et_pb_line_break_holder] -->    .faqdark-wrap {<!-- [et_pb_line_break_holder] -->        max-width: 900px;<!-- [et_pb_line_break_holder] -->        margin: auto;<!-- [et_pb_line_break_holder] -->        display: flex;<!-- [et_pb_line_break_holder] -->        flex-direction: column;<!-- [et_pb_line_break_holder] -->        gap: 18px;<!-- [et_pb_line_break_holder] -->    }<!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    .faqdark-item {<!-- [et_pb_line_break_holder] -->        border-radius: 12px;<!-- [et_pb_line_break_holder] -->        border: 1px solid rgba(255, 255, 255, .2);<!-- [et_pb_line_break_holder] -->        background: transparent;<!-- [et_pb_line_break_holder] -->        overflow: hidden;<!-- [et_pb_line_break_holder] -->    }<!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    .faqdark-head {<!-- [et_pb_line_break_holder] -->        display: flex;<!-- [et_pb_line_break_holder] -->        justify-content: space-between;<!-- [et_pb_line_break_holder] -->        align-items: center;<!-- [et_pb_line_break_holder] -->        gap: 18px;<!-- [et_pb_line_break_holder] -->        padding: 20px 22px;<!-- [et_pb_line_break_holder] -->        cursor: pointer;<!-- [et_pb_line_break_holder] -->    }<!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    .faqdark-title {<!-- [et_pb_line_break_holder] -->        font-size: 18px;<!-- [et_pb_line_break_holder] -->        font-weight: 600;<!-- [et_pb_line_break_holder] -->        color: #eaf2f4;<!-- [et_pb_line_break_holder] -->        line-height: 1.5;<!-- [et_pb_line_break_holder] -->    }<!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    .faqdark-icon {<!-- [et_pb_line_break_holder] -->        font-size: 32px;<!-- [et_pb_line_break_holder] -->        color: #fff;<!-- [et_pb_line_break_holder] -->        transition: transform .3s ease;<!-- [et_pb_line_break_holder] -->        flex-shrink: 0;<!-- [et_pb_line_break_holder] -->    }<!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    .faqdark-body {<!-- [et_pb_line_break_holder] -->        max-height: 0;<!-- [et_pb_line_break_holder] -->        overflow: hidden;<!-- [et_pb_line_break_holder] -->        transition: max-height .45s ease;<!-- [et_pb_line_break_holder] -->    }<!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    .faqdark-content {<!-- [et_pb_line_break_holder] -->        padding: 0 22px 24px 22px;<!-- [et_pb_line_break_holder] -->        color: #c9d6d9;<!-- [et_pb_line_break_holder] -->        line-height: 1.8;<!-- [et_pb_line_break_holder] -->        font-size: 15.5px;<!-- [et_pb_line_break_holder] -->    }<!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    .faqdark-item.active .faqdark-body {<!-- [et_pb_line_break_holder] -->        max-height: 1800px;<!-- [et_pb_line_break_holder] -->    }<!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    .faqdark-item.active .faqdark-icon {<!-- [et_pb_line_break_holder] -->        transform: rotate(45deg);<!-- [et_pb_line_break_holder] -->    }<!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    @media(max-width:600px) {<!-- [et_pb_line_break_holder] -->        .faqdark-head { padding: 18px; }<!-- [et_pb_line_break_holder] -->        .faqdark-content { padding: 0 18px 20px 18px; font-size: 15px; line-height: 1.75; }<!-- [et_pb_line_break_holder] -->        .faqdark-title { font-size: 16px; line-height: 1.45; }<!-- [et_pb_line_break_holder] -->        .faqdark-icon { font-size: 28px; }<!-- [et_pb_line_break_holder] -->    }<!-- [et_pb_line_break_holder] --><\/style>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->&#8220;`html<!-- [et_pb_line_break_holder] --><\/p>\n<div class=\"faqdark-wrap\"><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item active\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">What percentage of visceral fat does tesamorelin reduce?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                In Phase 3 clinical trials, tesamorelin reduced visceral adipose tissue by approximately 15\u201318% at 26 weeks, measured by CT scan, compared with a slight increase under placebo.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">How long does tesamorelin take to reduce visceral fat?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Research data showed measurable VAT separation from placebo by week 13, with the full reduction documented at the 26-week endpoint.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">What is the tesamorelin visceral fat reduction percentage at 26 weeks?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                The registrational Phase 3 trials reported roughly a 15\u201318% reduction in visceral adipose tissue at the 26-week mark.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">Is tesamorelin&#8217;s effect on visceral fat permanent?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                No. The research data indicate the effect is reversible \u2014 visceral fat tended to return after the peptide was discontinued, suggesting continued administration was needed to maintain it.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">What is tesamorelin?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog, a stabilized 44-amino-acid peptide studied for its selective reduction of visceral adipose tissue.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">How does tesamorelin reduce visceral fat?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                It stimulates the pituitary to release the body&#8217;s own growth hormone in natural pulses. Growth hormone promotes lipolysis, and visceral fat is especially sensitive to that effect.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">Does tesamorelin reduce subcutaneous fat too?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Research showed the reduction was largely selective for visceral fat, with comparatively little change in subcutaneous adipose tissue.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">What did tesamorelin Phase 3 trials show?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                They showed an approximately 15\u201318% reduction in visceral fat at 26 weeks, improved triglycerides, elevated IGF-1 as a pharmacodynamic marker, and reversibility on discontinuation.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">Is tesamorelin a growth hormone?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                No. It is a GHRH analog that signals the body to release its own growth hormone, rather than supplying growth hormone directly.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">What is the difference between tesamorelin and retatrutide?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Tesamorelin is a GHRH analog studied for selective visceral fat reduction; retatrutide is a triple-agonist studied for broad body-weight change.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">Why does tesamorelin raise IGF-1?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Because it stimulates growth hormone release, downstream IGF-1 rises. Researchers use this elevation as a marker confirming the compound is active.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">How is tesamorelin reconstituted in research?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                It is supplied lyophilized and reconstituted with bacteriostatic water; concentration math is confirmed before use, often with a reconstitution calculator.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">How should tesamorelin be stored?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Lyophilized peptide is stored cold and protected from light. Once reconstituted, the solution is refrigerated and used within a defined window.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">What is visceral adipose tissue (VAT)?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Visceral adipose tissue is fat stored around internal organs. It is metabolically active and a key endpoint in tesamorelin research.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">How is visceral fat measured in tesamorelin studies?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Trials measured VAT using single-slice CT imaging, typically at the L4\u2013L5 vertebral level, before and after the study period.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">Does tesamorelin affect liver fat?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Emerging research has examined tesamorelin&#8217;s effect on hepatic fat fraction in fatty-liver models, extending interest beyond visceral fat.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">Is tesamorelin selective for visceral fat?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Yes \u2014 selectivity for visceral over subcutaneous fat is one of the defining features of its research data.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">What class of peptide is tesamorelin?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                It is a growth hormone-releasing hormone (GHRH) analog.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">What is the latest tesamorelin research in 2025\u20132026?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Recent directions include hepatic fat studies, cardiometabolic marker analysis, cognitive-axis exploration, and combination protocol comparisons.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">How does tesamorelin compare to AOD-9604?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                AOD-9604 is a growth hormone fragment studied for lipolysis that does not raise IGF-1, whereas tesamorelin is a full GHRH analog that does.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">Why is tesamorelin&#8217;s data considered reliable?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Because it advanced through registrational Phase 3 trials with CT-measured endpoints across hundreds of subjects, producing a well-documented reference dataset.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">What triglyceride changes did tesamorelin show?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Trials reported reductions in triglycerides and improvements in several lipid parameters alongside the visceral fat reduction.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">Is tesamorelin used for research only?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                On this site, tesamorelin and all related compounds are supplied strictly for laboratory and in-vitro research use only.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->    <\/p>\n<div class=\"faqdark-item\"><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-head\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-title\">Where can I find verified tesamorelin research specifications?<\/div>\n<p><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-icon\">+<\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/p>\n<div class=\"faqdark-body\"><!-- [et_pb_line_break_holder] -->            <\/p>\n<div class=\"faqdark-content\"><!-- [et_pb_line_break_holder] -->                Reference-grade material with published certificates of analysis is available through 99 Purity Peptides&#8217; research catalog.<!-- [et_pb_line_break_holder] -->            <\/div>\n<p><!-- [et_pb_line_break_holder] -->        <\/div>\n<p><!-- [et_pb_line_break_holder] -->    <\/div>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/div>\n<p><!-- [et_pb_line_break_holder] -->&#8220;`<!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><script><!-- [et_pb_line_break_holder] -->    document.querySelectorAll(\".faqdark-head\").forEach(head => {<!-- [et_pb_line_break_holder] -->        head.addEventListener(\"click\", () => {<!-- [et_pb_line_break_holder] -->            const item = head.parentElement;<!-- [et_pb_line_break_holder] -->            if (item.classList.contains(\"active\")) {<!-- [et_pb_line_break_holder] -->                item.classList.remove(\"active\");<!-- [et_pb_line_break_holder] -->            } else {<!-- [et_pb_line_break_holder] -->                document.querySelectorAll(\".faqdark-item\").forEach(el => {<!-- [et_pb_line_break_holder] -->                    el.classList.remove(\"active\");<!-- [et_pb_line_break_holder] -->                });<!-- [et_pb_line_break_holder] -->                item.classList.add(\"active\");<!-- [et_pb_line_break_holder] -->            }<!-- [et_pb_line_break_holder] -->        });<!-- [et_pb_line_break_holder] -->    });<!-- [et_pb_line_break_holder] --><\/script>[\/et_pb_code][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;40px||||false|false&#8221; custom_padding=&#8221;||40px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Still have questions?&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Montserrat|700|||||||&#8221; title_text_align=&#8221;center&#8221; title_text_color=&#8221;#ffffff&#8221; title_font_size=&#8221;32px&#8221; title_line_height=&#8221;42px&#8221; custom_margin=&#8221;0px||0px||true|false&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#fafafa&#8221; text_line_height=&#8221;26px&#8221; text_orientation=&#8221;center&#8221; custom_margin=&#8221;0px||0px||true|false&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;]Reach out to our team anytime[\/et_pb_text][et_pb_button button_url=&#8221;\/contact-us&#8221; button_text=&#8221;contact&#8221; button_alignment=&#8221;center&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; button_text_size=&#8221;14px&#8221; button_text_color=&#8221;#ffffff&#8221; button_bg_color=&#8221;#1e5d68&#8243; button_border_radius=&#8221;8px&#8221; button_font=&#8221;&#8211;et_global_heading_font|600||on|||||&#8221; button_use_icon=&#8221;off&#8221; custom_margin=&#8221;10px||||false|false&#8221; custom_padding=&#8221;16px||16px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Last updated: June 24, 2026Few research peptides have a clinical record as specific as tesamorelin. Across multiple Phase 3 trials, the tesamorelin visceral fat reduction percentage has been measured directly with CT imaging, and the results are remarkably consistent. Researchers searching for hard numbers \u2014 not vague promises \u2014 keep arriving at the same question: [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6022,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"2880","footnotes":""},"categories":[97],"tags":[],"class_list":["post-6007","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-emerging-research"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tesamorelin Visceral Fat Reduction Percentage | Phase 3 Trial Data<\/title>\n<meta name=\"description\" content=\"What percentage of visceral fat does tesamorelin reduce in research? Phase 3 clinical trials report roughly an 18% VAT reduction near 26 weeks. Review the data, timelines, and reference standards.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/99puritypeptides.com\/es\/tesamorelin-visceral-fat-reduction-percentage\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tesamorelin Visceral Fat Reduction Percentage | Phase 3 Trial Data\" \/>\n<meta property=\"og:description\" content=\"What percentage of visceral fat does tesamorelin reduce in research? Phase 3 clinical trials report roughly an 18% VAT reduction near 26 weeks. Review the data, timelines, and reference standards.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/99puritypeptides.com\/es\/tesamorelin-visceral-fat-reduction-percentage\/\" \/>\n<meta property=\"og:site_name\" content=\"99 Purity Peptides\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T22:38:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-24T01:41:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/06\/visceral-adipose-tissue-around-organs.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Tech-Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"GHK-Cu Peptide: Complete Research Guide 2026 (45 chars)\" \/>\n<meta name=\"twitter:description\" content=\"GHK-Cu peptide research reference: mechanism, collagen pathway evidence, lab handling, purity standards, and 35+ FAQs from peer-reviewed studies.\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tech-Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutos\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tesamorelin Visceral Fat Reduction Percentage | Phase 3 Trial Data","description":"What percentage of visceral fat does tesamorelin reduce in research? Phase 3 clinical trials report roughly an 18% VAT reduction near 26 weeks. Review the data, timelines, and reference standards.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/99puritypeptides.com\/es\/tesamorelin-visceral-fat-reduction-percentage\/","og_locale":"es_MX","og_type":"article","og_title":"Tesamorelin Visceral Fat Reduction Percentage | Phase 3 Trial Data","og_description":"What percentage of visceral fat does tesamorelin reduce in research? Phase 3 clinical trials report roughly an 18% VAT reduction near 26 weeks. Review the data, timelines, and reference standards.","og_url":"https:\/\/99puritypeptides.com\/es\/tesamorelin-visceral-fat-reduction-percentage\/","og_site_name":"99 Purity Peptides","article_published_time":"2026-06-23T22:38:40+00:00","article_modified_time":"2026-06-24T01:41:08+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/06\/visceral-adipose-tissue-around-organs.webp","type":"image\/webp"}],"author":"Tech-Admin","twitter_card":"summary_large_image","twitter_title":"GHK-Cu Peptide: Complete Research Guide 2026 (45 chars)","twitter_description":"GHK-Cu peptide research reference: mechanism, collagen pathway evidence, lab handling, purity standards, and 35+ FAQs from peer-reviewed studies.","twitter_misc":{"Escrito por":"Tech-Admin","Tiempo de lectura":"14 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["Article","BlogPosting"],"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/#article","isPartOf":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/"},"author":{"name":"Tech-Admin","@id":"https:\/\/99puritypeptides.com\/#\/schema\/person\/e55552079f2f37ec910151ea4b2951dd"},"headline":"Tesamorelin &amp; Visceral Fat: Phase 3 VAT Reduction Data (2026)","datePublished":"2026-06-23T22:38:40+00:00","dateModified":"2026-06-24T01:41:08+00:00","mainEntityOfPage":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/"},"wordCount":5235,"publisher":{"@id":"https:\/\/99puritypeptides.com\/#organization"},"image":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/#primaryimage"},"thumbnailUrl":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/06\/visceral-adipose-tissue-around-organs-1-1.webp","articleSection":["Emerging research"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/","url":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/","name":"Tesamorelin Visceral Fat Reduction Percentage | Phase 3 Trial Data","isPartOf":{"@id":"https:\/\/99puritypeptides.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/#primaryimage"},"image":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/#primaryimage"},"thumbnailUrl":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/06\/visceral-adipose-tissue-around-organs-1-1.webp","datePublished":"2026-06-23T22:38:40+00:00","dateModified":"2026-06-24T01:41:08+00:00","description":"What percentage of visceral fat does tesamorelin reduce in research? Phase 3 clinical trials report roughly an 18% VAT reduction near 26 weeks. Review the data, timelines, and reference standards.","breadcrumb":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/#primaryimage","url":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/06\/visceral-adipose-tissue-around-organs-1-1.webp","contentUrl":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/06\/visceral-adipose-tissue-around-organs-1-1.webp","width":1254,"height":1254,"caption":"visceral adipose tissue around organs"},{"@type":"BreadcrumbList","@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-reduction-percentage\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/99puritypeptides.com\/"},{"@type":"ListItem","position":2,"name":"Tesamorelin &amp; Visceral Fat: Phase 3 VAT Reduction Data (2026)"}]},{"@type":"WebSite","@id":"https:\/\/99puritypeptides.com\/#website","url":"https:\/\/99puritypeptides.com\/","name":"99 Purity Peptides","description":"","publisher":{"@id":"https:\/\/99puritypeptides.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/99puritypeptides.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/99puritypeptides.com\/#organization","name":"99 Purity Peptides","url":"https:\/\/99puritypeptides.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/99puritypeptides.com\/#\/schema\/logo\/image\/","url":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2025\/12\/99-Purity-Peptides-logo.png","contentUrl":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2025\/12\/99-Purity-Peptides-logo.png","width":239,"height":100,"caption":"99 Purity Peptides"},"image":{"@id":"https:\/\/99puritypeptides.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/99puritypeptides.com\/#\/schema\/person\/e55552079f2f37ec910151ea4b2951dd","name":"Tech-Admin","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/40f1be3f1f5d04abecbd756bd94581cbf8ad889cae584be7a6fd1e9f8eacdd77?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/40f1be3f1f5d04abecbd756bd94581cbf8ad889cae584be7a6fd1e9f8eacdd77?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/40f1be3f1f5d04abecbd756bd94581cbf8ad889cae584be7a6fd1e9f8eacdd77?s=96&d=mm&r=g","caption":"Tech-Admin"},"sameAs":["https:\/\/99puritypeptides.com"]}]}},"_links":{"self":[{"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/posts\/6007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/comments?post=6007"}],"version-history":[{"count":7,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/posts\/6007\/revisions"}],"predecessor-version":[{"id":6030,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/posts\/6007\/revisions\/6030"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/media\/6022"}],"wp:attachment":[{"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/media?parent=6007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/categories?post=6007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/tags?post=6007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}